molecular pathways neurodegeneration parkinsons disease
parkinsons disease pd complex disorder many different causes yet may intersect common pathways raising possibility neuroprotective agents may broad applicability treatment pd current evidence suggests mitochondrial complex inhibition may central cause sporadic pd derangements complex cause alpha-synuclein aggregation contributes demise dopamine neurons accumulation aggregation alpha-synuclein may contribute death dopamine neurons impairments protein handling detoxification dysfunction parkin ubiquitin e3 ligase dj contribute deficits strategies aimed restoring complex activity reducing oxidative stress alpha-synuclein aggregation enhancing protein degradation may hold particular promise powerful neuroprotective agents treatment pd
